Latest On VistaGen Therapeutics, Inc (VTGN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-22 19:01 EST | News | Vistagen up 17% after Phase 3 data for anxiety candidate | N/A |  |
| 2023-03-03 13:33 EST | News | VistaGen readies 12M-share secondary offering | N/A | |
| 2023-03-01 18:06 EST | News | Vistagen secures new U.S. patent for PH80 nasal spray for migraine | N/A | |
| 2023-02-10 19:53 EST | News | VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript | N/A | |
| 2023-02-08 14:13 EST | News | VistaGen slips as mid-stage study for anxiety therapy remains on hold | N/A | |
| 2023-02-08 00:59 EST | News | VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.18M misses by $0.13M | N/A | |
| 2022-12-21 12:33 EST | News | VistaGen acquiring Pherin Pharma acquisition to bolster neuropsychiatric portfolio | N/A | |
| 2022-12-06 09:32 EST | News | Vistagen surges 30% on FDA fast track status for nasal spray for depression | N/A | |
| 2022-12-01 01:38 EST | News | Vistagen stock rises ~10% on FDA nod to proceed with trial for depression nasal spray | N/A | |
| 2022-11-11 01:04 EST | News | VistaGen Therapeutics GAAP EPS of -$0.08 | N/A | |
| 2022-11-11 01:03 EST | News | VistaGen Therapeutics, Inc. (VTGN) Q2 2023 Earnings Call Transcript | N/A | |
| 2022-11-10 07:32 EST | News | VistaGen Therapeutics Q2 2023 Earnings Preview | N/A | |
| 2022-09-08 19:24 EST | News | VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis | N/A | |
| 2022-08-13 02:54 EST | News | VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss | N/A | |
| 2022-08-13 02:54 EST | News | VistaGen Therapeutics, Inc.'s (VTGN) CEO Shawn Singh on Q1 2023 Results -Earnings Call Transcript | N/A | |
| 2022-08-11 17:37 EST | News | VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M beats by $0.07M | N/A | |
| 2022-08-11 01:22 EST | News | VistaGen Therapeutics FQ1 2023 Earnings Preview | N/A | |
| 2022-07-25 19:58 EST | News | VistaGen downgraded to neutral at Baird on pivotal trial failure | N/A | |
| 2022-07-23 00:11 EST | News | VistaGen drops 80% as late-stage study for anxiety therapy fails | N/A | |
| 2022-06-24 15:56 EST | News | VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results - Earnings Call Transcript | N/A | |
| 2022-06-24 15:55 EST | News | VistaGen stock down 7% on disappointing FY result | N/A | |
| 2022-06-23 22:04 EST | News | VistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03, revenue of $1.11M misses by $0.21M | N/A | |
| 2022-05-05 12:48 EST | News | VistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety | N/A | |
| 2022-04-12 18:53 EST | News | VistaGen, AffaMed plan to start global study of nasal spray PH94B for anxiety in H2 | N/A | |
| 2022-02-11 11:15 EST | News | VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-02-10 17:42 EST | News | VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11M | N/A | |
| 2022-02-09 20:44 EST | News | VistaGen Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2021-11-11 15:24 EST | News | VistaGen Therapeutics' (VTGN) CEO Shawn Singh on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2021-11-10 18:14 EST | News | VistaGen Therapeutics EPS misses by $0.01, beats on revenue | N/A | |
| 2021-11-09 19:29 EST | News | VistaGen Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2021-10-15 03:30 EST | News | VistaGen Therapeutics expands clinical development of PH94B in Adjustment Disorder with Anxiety | N/A | |
| 2021-08-13 02:49 EST | News | VistaGen Therapeutics EPS beats by $0.01, misses on revenue | N/A | |
| 2021-08-13 02:48 EST | News | VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2021-07-23 09:16 EST | News | VistaGen Therapeutics adds Maggie FitzPatrick to its board of directors | N/A | |
| 2021-07-22 08:46 EST | News | VistaGen initiates late-stage trial of PH94B in social anxiety disorder | N/A | |
| 2021-07-22 08:23 EST | News | VistaGen Therapeutics added to Russell 2000 Index | N/A | |
| 2021-07-22 08:04 EST | News | VistaGen Therapeutics EPS misses by $0.27, beats on revenue | N/A | |
| 2021-07-22 08:04 EST | News | VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-22 08:01 EST | News | VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow | N/A | |
| 2021-07-22 07:51 EST | News | VistaGen appoints Mary Rotunno to board of directors | N/A | |
| 2021-05-05 05:28 EST | News | VistaGen names new chief commercial officer | N/A | |
| 2021-04-26 09:15 EST | News | VistaGen Therapeutics: SAD And MDD Antidepressants May Finally Be Ready To Deliver | N/A | |
| 2021-04-25 13:31 EST | News | VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin | N/A | |
| 2021-03-17 11:31 EST | News | VistaGen Therapeutics files for $250M mixed shelf | N/A | |
| 2021-02-19 00:55 EST | Analyst Rating | The Analyst Target Price has increased from $5.5 to $5.67. | Buy | |
| 2021-02-19 00:15 EST | News | VistaGen initiated with Buy at Jefferies on 'upside potential' for anxiety drug | N/A | |
| 2021-02-12 12:35 EST | Earnings Estimate | An EPS average of -$0.05 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-12 08:46 EST | News | VistaGen Therapeutics EPS misses by $0.02, beats on revenue | N/A | |
| 2021-02-12 04:51 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-24 02:03 EST | News | VistaGen: Patience Could Lead To Significant Upside | N/A | |
About VistaGen Therapeutics, Inc (VTGN):
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
General
- Name VistaGen Therapeutics, Inc
- Symbol VTGN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 11
- Last Split Factor1:20
- Last Split Date2014-08-14
- Fiscal Year EndMarch
- IPO Date2016-05-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.vistagen.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 223.83
- Price/Book (Most Recent Quarter) 3.55
- Enterprise Value Revenue 359.11
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.23
- Next Year EPS Estimate -$0.25
- Next Quarter EPS Estimate -$0.04
- Operating Margin -2313%
- Return on Assets -16%
- Return on Equity -30%
- Revenue 647600
- Earnings Per Share -$0.83
- Revenue Per Share $0.01
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 324.19 million
- EBITDA -26467900
- Analyst Target Price $5.67
- Book Value Per Share $0.68
View More
Share Statistics
- Shares Outstanding 143.76 million
- Shares Float 109.05 million
- % Held by Insiders 448%
- % Held by Institutions 7.53%
- Shares Short 8.51 million
- Shares Short Prior Month 5.25 million
- Short Ratio 1.54
- Short % of Float 6%
- Short % of Shares Outstanding 6%
View More
Technicals
- Beta 0.88
- 52 Week High $3.18
- 52 Week Low $0.35
- 50 Day Moving Average 2.22
- 200 Day Moving Average 1.33
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
VistaGen Therapeutics, Inc (VTGN) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
VistaGen Therapeutics, Inc (VTGN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-11 | $313600 | -$0.07 | -$0.05 | -31.33% |
| 2020-09-30 | 2020-11-12 | $334000 | -$0.05 | -$0.02 | -114.59% |
| 2020-06-30 | 2020-08-13 | $N/A | -$0.07 | -$0.10 | 30% |
| 2020-03-31 | 2020-06-29 | $N/A | -$0.07 | -$0.08 | 12.5% |
| 2019-12-31 | 2020-02-13 | $N/A | -$0.15 | -$0.07 | -114.29% |
| 2019-09-30 | 2019-11-07 | $N/A | -$0.13 | -$0.14 | 3.7% |
| 2019-06-30 | 2019-08-13 | $N/A | -$0.15 | -$0.11 | -36.36% |
| 2019-03-31 | 2019-06-25 | $N/A | -$0.17 | -$0.21 | 19.05% |
| 2018-12-31 | 2019-02-12 | $N/A | -$0.24 | -$0.22 | -11.63% |
| 2018-09-30 | 2018-10-29 | $N/A | -$0.30 | -$0.17 | -76.47% |
| 2018-06-30 | 2018-08-14 | $N/A | -$0.20 | -$0.14 | -42.86% |
| 2018-03-31 | 2018-06-26 | $N/A | -$0.09 | -$0.28 | 67.39% |
| 2017-12-31 | 2018-02-12 | $N/A | -$0.23 | -$0.67 | 65.67% |
| 2017-09-30 | 2017-11-09 | $N/A | -$0.53 | -$0.47 | -13% |
| 2017-06-30 | 2017-08-14 | $N/A | -$0.28 | -$0.41 | 31.71% |
| 2017-03-31 | 2017-06-29 | $N/A | -$0.32 | -$0.52 | 38.46% |
| 2016-12-31 | 2017-02-13 | $1.25 million | -$0.34 | -$0.37 | 8.11% |
| 2016-09-30 | 2016-11-14 | $N/A | -$0.42 | -$0.38 | -10.53% |
| 2016-06-30 | 2016-08-12 | $N/A | -$0.51 | -$0.56 | 8.93% |
| 2016-03-31 | 2016-06-24 | $N/A | -$4.44 | -$1.80 | -146.67% |
| 2015-12-31 | 2016-02-16 | $N/A | -$1.95 | -$6.43 | 69.67% |
| 2015-09-30 | 2015-11-16 | $N/A | -$5.26 | ||
| 2015-06-30 | 2015-08-14 | $N/A | -$19.23 | ||
| 2015-03-31 | 2015-06-29 | $N/A | -$5.49 | -$0.84 | -553.57% |
| 2014-12-31 | 2015-02-17 | $N/A | -$1.08 | ||
| 2014-09-30 | 2014-11-19 | $N/A | -$1.90 | ||
| 2014-06-30 | 2014-08-12 | $N/A | -$3.70 | ||
| 2014-03-31 | 2014-03-31 | $N/A | -$1.57 | ||
| 2013-12-31 | 2013-12-31 | $N/A | -$0.44 | ||
| 2013-09-30 | 2013-09-30 | $N/A | -$1.35 | ||
| 2013-06-30 | 2013-06-30 | $N/A | -$0.44 | ||
| 2013-03-31 | 2013-03-31 | $200000 | -$3.73 | ||
| 2012-12-31 | 2012-12-31 | $N/A | -$13.62 | ||
| 2012-09-30 | 2012-09-30 | $-200000 | -$2.32 | ||
| 2012-06-30 | 2012-06-30 | $200000 | -$2.17 | ||
| 2012-03-31 | 2012-03-31 | $469000 | -$4.13 | ||
| 2011-12-31 | 2011-12-31 | $2000 | -$5.61 | ||
| 2011-09-30 | 2011-09-30 | $316000 | -$2.96 | ||
| 2011-06-30 | 2011-06-30 | $555000 | -$4.48 |
VistaGen Therapeutics, Inc (VTGN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
VistaGen Therapeutics, Inc (VTGN) Chart:
VistaGen Therapeutics, Inc (VTGN) News:
Below you will find a list of latest news for VistaGen Therapeutics, Inc (VTGN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
VistaGen Therapeutics, Inc (VTGN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 1 | 0 | CALL | 0 | 0 | 483.52 | TRUE | 0 | 0 |
| 2024-05-17 | 2 | 2.95 | CALL | 0 | 91 | 383.13 | TRUE | 0 | 0 |
| 2024-05-17 | 3 | 2.2 | CALL | 0 | 39 | 246.86 | TRUE | 0 | 0 |
| 2024-05-17 | 4 | 0.85 | CALL | 1 | 57 | 67.07 | TRUE | 0.85 | 0 |
| 2024-05-17 | 5 | 0.15 | CALL | 87 | 1408 | 47.63 | FALSE | -0.2 | -0.57 |
| 2024-05-17 | 6 | 0.15 | CALL | 18 | 2101 | 101.62 | FALSE | 0.01 | 0.07 |
| 2024-05-17 | 7 | 0.24 | CALL | 0 | 81 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 8 | 0.05 | CALL | 0 | 62 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 9 | 0.12 | CALL | 0 | 115 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 0.05 | CALL | 0 | 104 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 11 | 0.15 | CALL | 0 | 11 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12 | 0.05 | CALL | 0 | 96 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 13 | 0.25 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 3 | 0.9 | PUT | 0 | 6 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 4 | 0.13 | PUT | 0 | 906 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.53 | PUT | 12 | 116 | 84.16 | TRUE | 0.53 | 0 |
| 2024-05-17 | 6 | 1.35 | PUT | 0 | 3 | 107.38 | TRUE | 0 | 0 |
| 2024-05-17 | 7 | 0 | PUT | 0 | 0 | 202.36 | TRUE | 0 | 0 |
| 2024-05-17 | 8 | 0 | PUT | 0 | 0 | 183.54 | TRUE | 0 | 0 |
| 2024-05-17 | 9 | 0 | PUT | 0 | 0 | 309.75 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 193.31 | TRUE | 0 | 0 |
| 2024-05-17 | 11 | 0 | PUT | 0 | 0 | 232.29 | TRUE | 0 | 0 |
| 2024-05-17 | 12 | 0 | PUT | 0 | 0 | 197.17 | TRUE | 0 | 0 |
| 2024-05-17 | 13 | 0 | PUT | 0 | 0 | 413.71 | TRUE | 0 | 0 |
| 2024-06-21 | 1 | 0 | CALL | 0 | 0 | 305.3 | TRUE | 0 | 0 |
| 2024-06-21 | 2 | 0 | CALL | 0 | 0 | 173.81 | TRUE | 0 | 0 |
| 2024-06-21 | 3 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 4 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 6 | 0.25 | CALL | 70 | 0 | 79.71 | FALSE | 0.25 | 0 |
| 2024-06-21 | 7 | 0 | CALL | 0 | 0 | 179.5 | FALSE | 0 | 0 |
| 2024-06-21 | 8 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 9 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 3 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 4 | 0 | PUT | 0 | 0 | 406.91 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 6 | 0 | PUT | 0 | 0 | 226.65 | TRUE | 0 | 0 |
| 2024-06-21 | 7 | 0 | PUT | 0 | 0 | 117.5 | TRUE | 0 | 0 |
| 2024-06-21 | 8 | 0 | PUT | 0 | 0 | 121.66 | TRUE | 0 | 0 |
| 2024-06-21 | 9 | 0 | PUT | 0 | 0 | 432.26 | TRUE | 0 | 0 |
| 2024-08-16 | 1 | 0 | CALL | 0 | 0 | 242.24 | TRUE | 0 | 0 |
| 2024-08-16 | 2 | 4.2 | CALL | 0 | 3 | 143.85 | TRUE | 0 | 0 |
| 2024-08-16 | 3 | 1.58 | CALL | 0 | 4 | 74.21 | TRUE | 0 | 0 |
| 2024-08-16 | 4 | 1.3 | CALL | 0 | 14 | 95.13 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0.9 | CALL | 0 | 46 | 87.56 | FALSE | 0 | 0 |
| 2024-08-16 | 6 | 0.55 | CALL | 0 | 1130 | 114.01 | FALSE | 0 | 0 |
| 2024-08-16 | 7 | 0.05 | CALL | 0 | 14 | 120.41 | FALSE | 0 | 0 |
| 2024-08-16 | 8 | 0.3 | CALL | 0 | 2862 | 145.98 | FALSE | 0 | 0 |
| 2024-08-16 | 9 | 0.61 | CALL | 0 | 5 | 90.21 | FALSE | 0 | 0 |
| 2024-08-16 | 10 | 0.2 | CALL | 0 | 149 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 3 | 0 | PUT | 0 | 0 | 137.15 | FALSE | 0 | 0 |
| 2024-08-16 | 4 | 0.5 | PUT | 6 | 506 | 88.76 | FALSE | 0.5 | 0 |
| 2024-08-16 | 5 | 1 | PUT | 0 | 54 | 78.67 | TRUE | 0 | 0 |
| 2024-08-16 | 6 | 0 | PUT | 0 | 0 | 101.47 | TRUE | 0 | 0 |
| 2024-08-16 | 7 | 0 | PUT | 0 | 0 | 103.31 | TRUE | 0 | 0 |
| 2024-08-16 | 8 | 0 | PUT | 0 | 0 | 119.83 | TRUE | 0 | 0 |
| 2024-08-16 | 9 | 0 | PUT | 0 | 0 | 104.38 | TRUE | 0 | 0 |
| 2024-08-16 | 10 | 0 | PUT | 0 | 0 | 128.37 | TRUE | 0 | 0 |
| 2024-11-15 | 1 | 0 | CALL | 0 | 0 | 129.09 | TRUE | 0 | 0 |
| 2024-11-15 | 2 | 0 | CALL | 0 | 0 | 96.97 | TRUE | 0 | 0 |
| 2024-11-15 | 3 | 0 | CALL | 0 | 0 | 42.37 | TRUE | 0 | 0 |
| 2024-11-15 | 4 | 0 | CALL | 0 | 0 | 79.43 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | CALL | 0 | 0 | 90.76 | FALSE | 0 | 0 |
| 2024-11-15 | 6 | 0 | CALL | 0 | 0 | 83.76 | FALSE | 0 | 0 |
| 2024-11-15 | 7 | 0.65 | CALL | 0 | 1 | 88.73 | FALSE | 0 | 0 |
| 2024-11-15 | 8 | 0 | CALL | 0 | 0 | 93.45 | FALSE | 0 | 0 |
| 2024-11-15 | 9 | 0.15 | CALL | 0 | 5 | 133.8 | FALSE | 0 | 0 |
| 2024-11-15 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 3 | 0 | PUT | 0 | 0 | 95.17 | FALSE | 0 | 0 |
| 2024-11-15 | 4 | 0.95 | PUT | 0 | 565 | 110.91 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 1.3 | PUT | 0 | 11 | 106.47 | TRUE | 0 | 0 |
| 2024-11-15 | 6 | 0 | PUT | 0 | 0 | 105.17 | TRUE | 0 | 0 |
| 2024-11-15 | 7 | 0 | PUT | 0 | 0 | 98.99 | TRUE | 0 | 0 |
| 2024-11-15 | 8 | 0 | PUT | 0 | 0 | 108.65 | TRUE | 0 | 0 |
| 2024-11-15 | 9 | 0 | PUT | 0 | 0 | 100.63 | TRUE | 0 | 0 |
| 2025-01-17 | 2 | 2.44 | CALL | 0 | 41 | 127.11 | TRUE | 0 | 0 |
| 2025-01-17 | 3 | 2.54 | CALL | 0 | 19 | 68.3 | TRUE | 0 | 0 |
| 2025-01-17 | 4 | 1.8 | CALL | 0 | 51 | 75.69 | TRUE | 0 | 0 |
| 2025-01-17 | 5 | 1.5 | CALL | 1 | 89 | 94.7 | FALSE | 0.05 | 0.03 |
| 2025-01-17 | 6 | 0 | CALL | 0 | 0 | 89.28 | FALSE | 0 | 0 |
| 2025-01-17 | 7 | 1.4 | CALL | 0 | 211 | 115.24 | FALSE | 0 | 0 |
| 2025-01-17 | 8 | 0 | CALL | 0 | 0 | 87.47 | FALSE | 0 | 0 |
| 2025-01-17 | 10 | 0.47 | CALL | 0 | 518 | 84.73 | FALSE | 0 | 0 |
| 2025-01-17 | 12 | 0.42 | CALL | 0 | 321 | 86.16 | FALSE | 0 | 0 |
| 2025-01-17 | 2 | 0.6 | PUT | 0 | 1 | 93.63 | FALSE | 0 | 0 |
| 2025-01-17 | 3 | 0.5 | PUT | 0 | 34 | 97.19 | FALSE | 0 | 0 |
| 2025-01-17 | 4 | 1.05 | PUT | 0 | 2 | 100.25 | FALSE | 0 | 0 |
| 2025-01-17 | 5 | 1.98 | PUT | 0 | 70 | 108.03 | TRUE | 0 | 0 |
| 2025-01-17 | 6 | 0 | PUT | 0 | 0 | 103.2 | TRUE | 0 | 0 |
| 2025-01-17 | 7 | 0 | PUT | 0 | 0 | 102.66 | TRUE | 0 | 0 |
| 2025-01-17 | 8 | 0 | PUT | 0 | 0 | 106.91 | TRUE | 0 | 0 |
| 2025-01-17 | 10 | 0 | PUT | 0 | 0 | 102.68 | TRUE | 0 | 0 |
| 2025-01-17 | 12 | 0 | PUT | 0 | 0 | 101.58 | TRUE | 0 | 0 |
| 2026-01-16 | 2 | 4.15 | CALL | 0 | 5 | 81.95 | TRUE | 0 | 0 |
| 2026-01-16 | 3 | 3.1 | CALL | 0 | 36 | 160.76 | TRUE | 0 | 0 |
| 2026-01-16 | 4 | 2.1 | CALL | 0 | 5 | 83.8 | TRUE | 0 | 0 |
| 2026-01-16 | 5 | 2.2 | CALL | 0 | 122 | 91.53 | FALSE | 0 | 0 |
| 2026-01-16 | 7 | 1.85 | CALL | 0 | 22 | 74.39 | FALSE | 0 | 0 |
| 2026-01-16 | 10 | 1.6 | CALL | 0 | 607 | 172.44 | FALSE | 0 | 0 |
| 2026-01-16 | 12 | 1.55 | CALL | 0 | 80 | 98.59 | FALSE | 0 | 0 |
| 2026-01-16 | 2 | 0 | PUT | 0 | 0 | 141.36 | FALSE | 0 | 0 |
| 2026-01-16 | 3 | 0.91 | PUT | 0 | 55 | 136.36 | FALSE | 0 | 0 |
| 2026-01-16 | 4 | 2.06 | PUT | 0 | 1 | 113.71 | FALSE | 0 | 0 |
| 2026-01-16 | 5 | 0 | PUT | 0 | 0 | 104.44 | TRUE | 0 | 0 |
| 2026-01-16 | 7 | 0 | PUT | 0 | 0 | 102.22 | TRUE | 0 | 0 |
| 2026-01-16 | 10 | 0 | PUT | 0 | 0 | 105.83 | TRUE | 0 | 0 |
| 2026-01-16 | 12 | 0 | PUT | 0 | 0 | 142.8 | TRUE | 0 | 0 |
Latest VTGN Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:53 PM EST | 200 | $0.9301 |
| Jun 13, 2022 7:54 PM EST | 100 | $0.9373 |
| Jun 13, 2022 7:58 PM EST | 57 | $0.9504 |
| Jun 13, 2022 7:58 PM EST | 200 | $0.9401 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.94 |
VistaGen Therapeutics, Inc (VTGN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001767/0001415889-20-001767-index.htm |
| 2019-10-03 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1411685/000000000019014276/0000000000-19-014276-index.htm |
| 2020-04-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1411685/000000000020002992/0000000000-20-002992-index.htm |
| 2020-05-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1411685/000000000020004027/0000000000-20-004027-index.htm |
| 2020-09-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1411685/000101905620000505/0001019056-20-000505-index.htm |
| 2020-01-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1411685/000110465920007804/0001104659-20-007804-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1411685/000117891319000442/0001178913-19-000442-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1411685/000117891320000343/0001178913-20-000343-index.htm |
| 2019-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1411685/000121390019001922/0001213900-19-001922-index.htm |
| 2018-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588918001318/0001415889-18-001318-index.htm |
| 2018-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588918001319/0001415889-18-001319-index.htm |
| 2018-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588918001320/0001415889-18-001320-index.htm |
| 2018-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588918001321/0001415889-18-001321-index.htm |
| 2018-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588918001322/0001415889-18-001322-index.htm |
| 2018-09-21 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588918001409/0001415889-18-001409-index.htm |
| 2019-01-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000050/0001415889-19-000050-index.htm |
| 2019-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000051/0001415889-19-000051-index.htm |
| 2019-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000052/0001415889-19-000052-index.htm |
| 2019-01-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm |
| 2019-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000107/0001415889-19-000107-index.htm |
| 2019-02-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000179/0001415889-19-000179-index.htm |
| 2019-03-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000287/0001415889-19-000287-index.htm |
| 2019-03-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000320/0001415889-19-000320-index.htm |
| 2019-03-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000322/0001415889-19-000322-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000581/0001415889-19-000581-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000583/0001415889-19-000583-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000585/0001415889-19-000585-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000587/0001415889-19-000587-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000589/0001415889-19-000589-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000591/0001415889-19-000591-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000593/0001415889-19-000593-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000595/0001415889-19-000595-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000597/0001415889-19-000597-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001207/0001415889-19-001207-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001208/0001415889-19-001208-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001209/0001415889-19-001209-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001210/0001415889-19-001210-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001211/0001415889-19-001211-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001212/0001415889-19-001212-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001213/0001415889-19-001213-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001214/0001415889-19-001214-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001215/0001415889-19-001215-index.htm |
| 2019-11-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001357/0001415889-19-001357-index.htm |
| 2019-12-12 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001479/0001415889-19-001479-index.htm |
| 2020-01-31 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920000199/0001415889-20-000199-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001060/0001415889-20-001060-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001061/0001415889-20-001061-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001062/0001415889-20-001062-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001063/0001415889-20-001063-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001064/0001415889-20-001064-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001065/0001415889-20-001065-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001066/0001415889-20-001066-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001067/0001415889-20-001067-index.htm |
| 2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001068/0001415889-20-001068-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001764/0001415889-20-001764-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001765/0001415889-20-001765-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001766/0001415889-20-001766-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001767/0001415889-20-001767-index.htm |
| 2020-08-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1411685/000141588920002181/0001415889-20-002181-index.htm |
| 2019-01-03 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1411685/000153561019000010/0001535610-19-000010-index.htm |
| 2018-09-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495418010158/0001654954-18-010158-index.htm |
| 2018-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495418010271/0001654954-18-010271-index.htm |
| 2018-10-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495418010862/0001654954-18-010862-index.htm |
| 2018-10-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495418011619/0001654954-18-011619-index.htm |
| 2018-10-29 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495418011665/0001654954-18-011665-index.htm |
| 2018-10-30 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495418011715/0001654954-18-011715-index.htm |
| 2018-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495418011717/0001654954-18-011717-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495418012521/0001654954-18-012521-index.htm |
| 2018-12-13 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495418013924/0001654954-18-013924-index.htm |
| 2019-01-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419000399/0001654954-19-000399-index.htm |
| 2019-01-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419000496/0001654954-19-000496-index.htm |
| 2019-02-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419000925/0001654954-19-000925-index.htm |
| 2019-02-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495419001372/0001654954-19-001372-index.htm |
| 2019-02-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495419001943/0001654954-19-001943-index.htm |
| 2019-02-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495419002032/0001654954-19-002032-index.htm |
| 2019-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419002248/0001654954-19-002248-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419002743/0001654954-19-002743-index.htm |
| 2019-04-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419004073/0001654954-19-004073-index.htm |
| 2019-05-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419005208/0001654954-19-005208-index.htm |
| 2019-06-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419007549/0001654954-19-007549-index.htm |
| 2019-06-25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1411685/000165495419007632/0001654954-19-007632-index.htm |
| 2019-07-12 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1411685/000165495419008227/0001654954-19-008227-index.htm |
| 2019-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419008430/0001654954-19-008430-index.htm |
| 2019-07-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1411685/000165495419008434/0001654954-19-008434-index.htm |
| 2019-07-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1411685/000165495419008511/0001654954-19-008511-index.htm |
| 2019-07-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1411685/000165495419008514/0001654954-19-008514-index.htm |
| 2019-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495419009386/0001654954-19-009386-index.htm |
| 2019-08-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419009727/0001654954-19-009727-index.htm |
| 2019-08-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419009965/0001654954-19-009965-index.htm |
| 2019-09-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419010432/0001654954-19-010432-index.htm |
| 2019-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419011097/0001654954-19-011097-index.htm |
| 2019-09-30 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1411685/000165495419011259/0001654954-19-011259-index.htm |
| 2019-10-01 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1411685/000165495419011260/0001654954-19-011260-index.htm |
| 2019-10-01 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1411685/000165495419011261/0001654954-19-011261-index.htm |
| 2019-10-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1411685/000165495419011429/0001654954-19-011429-index.htm |
| 2019-10-04 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1411685/000165495419011430/0001654954-19-011430-index.htm |
| 2019-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419011552/0001654954-19-011552-index.htm |
| 2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419012073/0001654954-19-012073-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495419012431/0001654954-19-012431-index.htm |
| 2019-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419012501/0001654954-19-012501-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419012881/0001654954-19-012881-index.htm |
| 2019-12-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419013881/0001654954-19-013881-index.htm |
| 2019-12-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495419014268/0001654954-19-014268-index.htm |
| 2020-01-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420000737/0001654954-20-000737-index.htm |
| 2020-01-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420000744/0001654954-20-000744-index.htm |
| 2020-01-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420001014/0001654954-20-001014-index.htm |
| 2020-02-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420001517/0001654954-20-001517-index.htm |
| 2020-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420001518/0001654954-20-001518-index.htm |
| 2020-02-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420001787/0001654954-20-001787-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420003246/0001654954-20-003246-index.htm |
| 2020-03-31 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1411685/000165495420003617/0001654954-20-003617-index.htm |
| 2020-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420003788/0001654954-20-003788-index.htm |
| 2020-04-10 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1411685/000165495420003958/0001654954-20-003958-index.htm |
| 2020-04-10 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1411685/000165495420003959/0001654954-20-003959-index.htm |
| 2020-04-15 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420004113/0001654954-20-004113-index.htm |
| 2020-04-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420004484/0001654954-20-004484-index.htm |
| 2020-04-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420004559/0001654954-20-004559-index.htm |
| 2020-05-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1411685/000165495420004837/0001654954-20-004837-index.htm |
| 2020-05-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1411685/000165495420005108/0001654954-20-005108-index.htm |
| 2020-05-11 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1411685/000165495420005109/0001654954-20-005109-index.htm |
| 2020-05-15 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420005649/0001654954-20-005649-index.htm |
| 2020-05-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420005728/0001654954-20-005728-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420006204/0001654954-20-006204-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420007024/0001654954-20-007024-index.htm |
| 2020-06-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420007107/0001654954-20-007107-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420007163/0001654954-20-007163-index.htm |
| 2020-07-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420007962/0001654954-20-007962-index.htm |
| 2020-07-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1411685/000165495420008042/0001654954-20-008042-index.htm |
| 2020-07-27 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1411685/000165495420008044/0001654954-20-008044-index.htm |
| 2020-07-31 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420008269/0001654954-20-008269-index.htm |
| 2020-08-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420008335/0001654954-20-008335-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420008543/0001654954-20-008543-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1411685/000165495420009069/0001654954-20-009069-index.htm |
| 2020-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420009204/0001654954-20-009204-index.htm |
| 2020-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420010220/0001654954-20-010220-index.htm |
| 2020-10-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1411685/000165495420011086/0001654954-20-011086-index.htm |
| 2019-10-07 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1411685/999999999519002263/9999999995-19-002263-index.htm |
| 2020-04-14 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1411685/999999999520000750/9999999995-20-000750-index.htm |
| 2020-05-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1411685/999999999520001147/9999999995-20-001147-index.htm |
| 2018-10-01 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1411685/999999999718008248/9999999997-18-008248-index.htm |
| 2018-12-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1411685/999999999718009564/9999999997-18-009564-index.htm |
VistaGen Therapeutics, Inc (VTGN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of VistaGen Therapeutics, Inc (VTGN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 448%Institutional Ownership: 753%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-03-13 | JON S SAXE | Director | Buy | 12,080.00 | 1.26 | 15,201.47 | 12,080.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000322/0001415889-19-000322-index.htm |
| 2019-11-20 | H. RALPH SNODGRASS | PRES./CHIEF SCIENTIFIC OFFICER | Buy | 15,000.00 | 0.34 | 5,100.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919001357/0001415889-19-001357-index.htm |
| 2019-03-14 | JON S SAXE | Director | Buy | 7,920.00 | 1.27 | 10,086.12 | 20,000.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000322/0001415889-19-000322-index.htm |
| 2019-01-14 | Shawn Singh | CHIEF EXECUTIVE OFFICER | Buy | 21,250.00 | 1.50 | 31,875.00 | 21,250.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm |
| 2019-01-14 | Shawn Singh | CHIEF EXECUTIVE OFFICER | Buy | 1,125.00 | 1.50 | 1,687.50 | 22,375.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm |
| 2019-01-29 | JON S SAXE | Director | Buy | 375.00 | 1.50 | 562.50 | 2,251.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000107/0001415889-19-000107-index.htm |
| 2019-01-14 | Shawn Singh | CHIEF EXECUTIVE OFFICER | Buy | 3,000.00 | 1.50 | 4,500.00 | 25,375.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm |
| 2020-06-30 | Shawn Singh | CHIEF EXECUTIVE OFFICER | Buy | 5,000.00 | 0.45 | 2,240.00 | 30,375.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001764/0001415889-20-001764-index.htm |
| 2019-01-29 | JON S SAXE | Director | Buy | 1,000.00 | 1.50 | 1,500.00 | 3,251.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000107/0001415889-19-000107-index.htm |
| 2020-06-30 | JERROLD DUANE DOTSON | VP, CFO AND SECRETARY | Buy | 5,000.00 | 0.45 | 2,240.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001765/0001415889-20-001765-index.htm |
| 2020-06-30 | Mark Alan Smith | CHIEF MEDICAL OFFICER | Buy | 5,000.00 | 0.45 | 2,240.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001766/0001415889-20-001766-index.htm |
| 2020-08-21 | JON S SAXE | Director | Buy | 30,000.00 | 0.69 | 20,700.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588920002181/0001415889-20-002181-index.htm |
| 2019-03-13 | H. RALPH SNODGRASS | PRES./CHIEF SCIENTIFIC OFFICER | Buy | 2,500.00 | 1.50 | 3,750.00 | 62,724.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588919000320/0001415889-19-000320-index.htm |
| 2020-06-30 | H. RALPH SNODGRASS | PRES./CHIEF SCIENTIFIC OFFICER | Buy | 5,000.00 | 0.45 | 2,240.00 | 67,724.00 | https://www.sec.gov/Archives/edgar/data/1411685/000141588920001767/0001415889-20-001767-index.htm |